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Engineering of Extracellular 




Extracellular vesicles are membrane-derived nanoparticles that represent a novel 
mechanism of cell-to-cell communication. It is well reported that EVs play a central 
role in the tumor microenvironment by mediating intercellular signaling among 
cancer cells. This has resulted in the development of therapeutic strategies targeting 
various EV signaling pathways in cancer. However, because of their small size and 
endogenous origin, they have been extensively explored for cancer drug delivery. 
Hence, owing to their natural ability to mediate intercellular communication, high sta-
bility, and low immunogenicity, they have emerged as an attractive platform for cancer 
treatment. However, limited production and insufficient loading with therapeutic 
moieties are some of the issues constraining their clinical translation. In this chapter, 
recent research studies performed in an attempt to develop EVs as cancer biomarkers 
or drug delivery systems will be discussed. Further, it will also discuss various strate-
gies such as direct and indirect cell surface modification, which can be employed to 
make EVs successful as cancer therapeutics. Furthermore, it will highlight the current 
and completed clinical trials using naturally derived EVs as cancer therapeutics.
Keywords: breast cancer, extracellular vesicles, engineering, drug delivery, 
biomarker
1. Introduction
In women, breast cancer is a prevalent cause of cancer worldwide [1]. It affected 
2.3 million women globally in 2020, with 685,000 deaths. It has been diagnosed in 
7.8 million women in the past 5 years, making it the most common type of cancer in 
the world [1]. Although breast cancer diagnostic methods and therapeutic proce-
dures have improved in the past decade, the long-term survival of these patients 
remains low due to a high rate of postsurgical relapse. The efficacy of breast cancer 
treatment is limited by drug toxicity, multidrug resistance, and a lack of definitive 
prognostic biomarkers [2]. Thus, there is an urgent need to develop novel biomark-
ers and therapeutics to cure the disease.
In recent years, many studies have suggested that intercellular communication plays 
a key role in driving various cellular functions and homeostasis in physiological as well 
as pathological conditions such as cancer, cardiovascular diseases, and neurological 
disorders. Cancer development is mainly dependent on interactions between cancerous 
cells and their microenvironment components. Some of these interactions are mediated 
by extracellular vesicles, which alter the phenotype of recipient cells [3–5].
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Extracellular vesicles (EVs) are spherical nanoparticles shed by all types of cells, 
including archaea, prokaryotes, eukaryotes, and fungi in the extracellular milieu 
[6]. These typically range from 30 nm to 5 μm in diameter based on their type 
and vary widely in composition [7]. In addition to being released during disease 
pathology, EVs allow various cells to send and receive messages to crosstalk with 
other cells, thus carrying out various biological functions [7]. These are mainly 
composed of different proteins, lipids, nucleic acids, and enzymes [8]. EVs circulate 
through many body fluids, such as blood, serum, and urine. Owing to their struc-
tural similarity to the parental source, they are considered potential biomarkers for 
diseases such as cancer [9]. To study the characteristics and functions of EVs, they 
are isolated using different techniques such as differential ultracentrifugation, size-
exclusion, and ultrafiltration [10].
EVs are generally categorized into exosomes, microvesicles, and apoptotic 
bodies according to their release mechanism, size, and composition [3]. Exosomes 
are 30–150 nm in diameter and are formed by inward budding of the plasma 
membrane of the cell [9]. Microvesicles are formed by direct outward budding of 
the cell’s plasma membrane and range in size from 100 to 1000 nm in diameter. 
Consequently, they are reported to contain mainly cytosolic and plasma membrane 
proteins, such as tetraspanins. Apoptotic bodies are shed during cell death into 
the extracellular space, ranging from 50 to 5000 nm in diameter. These generally 
contain intact organelles, glycosylated proteins, and chromatin, unlike the other 
two types of EVs. Among these, exosomes have been widely studied since their 
role in intercellular communication has been reported. This chapter will focus on 
exosomes and their potential applications as therapeutics for breast cancer.
2. Biogenesis, contents and functions of exosomes
Exosomes are generated by the endocytic pathway from late endosomes (LE) 
[11, 12]. LEs are formed by inward budding of the multivesicular body (MVB) 
membrane. LE membranes invaginate to form intraluminal vesicles (ILVs) within 
MVBs. During this process, some proteins are engulfed and packaged within the 
ILVs. ILVs then fuse with the cell’s plasma membrane and release the vesicles into the 
extracellular space.
As reported previously, the formation of ILVs can occur either dependent or inde-
pendent of the ESCRT complex. The ESCRT complex is a set of proteins that function 
together to facilitate the formation of MVBs, vesicle release, and protein cargo sorting 
[13–15]. ESCRT 0 has two subunits, HRS and STAM ½, which bind together and 
recognize specific ubiquitinated proteins in early endosomes. This leads to the recruit-
ment of ESCRT 1 containing Tsg 101, Vps28, Vps37, and Mvb 12, which further recruits 
ESCRT II. ESCRT II is composed of four subunits, Vps22-EAP30, Vps36—EAP45 and 
Vps25—EAP20 which starts the invagination of endosomal membranes encapsulating 
different molecules/cargo such as proteins and nucleic acids. The ESCRT II subunit 
Vsp25 then binds with Vsp20 to activate and recruit ESCRT III. It deubiquitinates 
proteins and allows complete membrane invagination, generating ILVs. Other adaptor 
proteins such as Vps4 interact with ESCRT III to finally start budding of the membrane, 
ECSRT subunit removal, and cargo delivery. Hence, the ESCRT complex regulates the 
whole process of vesicle budding and cargo sorting into exosomes [16, 17]. In cancer, an 
increased amount of exosomes is often observed in the bodily fluids of cancer patients 
as a result of deregulation of exosomal formation and secretion [18]. Specifically, in 
breast cancer, the amount of exosomes released by the human tumor cell line B42 clone 
16 was much larger than that released by the parental normal mammary epithelial cells 
(HMEC B42), as shown by Azmi et al. [19].
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Exosomes are composed of a heterogeneous set of cytosolic, nuclear, mitochon-
drial, ribosomal, and membrane-bound proteins derived from donor cells [20]. 
Some of these proteins are conserved irrespective of their origin; therefore, they 
are considered exosomal markers such as tetraspanins, ESCRT proteins, and major 
histocompatibility complex (MHC) molecules [21]. In addition, some proteins are 
related to the phenotype of producing cells, such as cancer-derived exosomes, which 
in turn determines their biological mechanisms. The lipid bilayer membrane of exo-
somes contains transmembrane proteins, transporter proteins, adhesion molecules, 
and lipid raft-associated proteins. Exosomes contain nucleic acids such as DNA 
(ssDNA, mtDNA, dsDNA, and RNA (mRNA, miRNA, and lncRNA) [22]. Exosomal 
miRNAs and mRNAs are transferred from donor cells to recipient cells, thus modu-
lating the latter’s phenotype. Although there are numerous reports indicating the 
presence of DNA within exosomes, the mechanisms leading to this phenomenon 
remain unclear. Exosomes also exhibit an exclusive set of lipids distributed in their 
bilayers, such as sphingolipids, arachidonic acid, cholesterol, phosphatidylserine, 
and ganglioside [23, 24]. Lipids such as lysobisphosphatidic acid are abundant in the 
inner membranes of multivesicular bodies and play a crucial role in exosome forma-
tion [25, 26]. ExoCarta is a database containing all the data on exosomal content, 
with over 47,000 protein, mRNA, and lipid entries. Furthermore, ExoCarta is an 
excellent source of information for exosome characterization (Figure 1) [27].
3. Functional role of exosomes in breast cancer development
Metastasis is the process by which primary tumor cells/tumor cells/cancer cells 
invade the surrounding tissues and colonize the blood vessels to proliferate and give 
rise to the tumor [28]. Controlling metastasis, which is mainly responsible for high 
patient mortality, is the main challenge in breast cancer therapy. Hence, several 
Figure 1. 
Schematic representation of exosome biogenesis and composition. Exosomes originate from multivesicular 
bodies and shed into extracellular space packaging motley of proteins such as ESCRT associated protein, 
chaperones, along with ssDNA, RNA and dsDNA, miRNA and lncRNA.
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investigations are ongoing to understand the molecular mechanisms underlying 
metastasis in breast cancer. Recently, exosomes have attracted great attention as key 
players in regulating complex intracellular pathways from initiation to progression 
to metastasis in the development of breast cancer [29–31]. These mainly interact 
with the recipient cells in three ways: direct fusion with the cell membrane, interac-
tion with the surface receptors, or internalization via endocytosis. Upon cellular 
uptake, exosomes deliver their cargo and initiate a cascade of events leading to vari-
ous biological functions. Many breast cancer cell lines have been shown to release 
exosomes containing several proteins with signaling molecules, miRNAs, and long 
non-coding RNAs involved in migration, invasion, angiogenesis, and metastasis 
[32–34]. Proteomic profiling of exosomes secreted from breast cancer cell lines was 
shown to contain matrix metalloproteinases, which might be linked to the enhanced 
metastatic properties of breast cancer cells [32]. These findings suggest that exo-
somes act as key mediators in the tumor microenvironment by communicating 
various signaling molecules essential for breast cancer development [31].
Exosome-mediated transfer of genetic material from breast cancer cells has been 
shown to mediate resistance to chemotherapy and enhance tumor growth [35, 36]. 
Accumulating evidence suggests that exosomes may also play a role in the resistance 
of breast cancer radiotherapy and cancer immunotherapy [37, 38]. In breast cancer, 
drug-resistant cancer cells transmit resistance in drug-sensitive cells via the inter-
cellular horizontal transfer of exosomal miRNAs [38]. Exosomes also transfer the 
drug efflux pump from docetaxel-resistant to sensitive ones in MCF-7 breast cancer 
cells [39]. Lv MM et al. showed that exosomes from drug-resistant cancer cells 
contain miRNAs that alter the phenotype of recipient breast cancer cells by altering 
their transcriptome [40]. Exosomes from stromal fibroblasts transmit non-coding 
RNA to breast cancer cells, thus contributing to treatment resistance by expand-
ing therapy-resistant cells [41]. Thus, exosomes contribute to drug resistance in 
breast cancer.
4. Therapeutic implication of EVs in breast cancer
The role of exosomes in carcinogenesis has been extensively investigated in 
recent years. Cancer cells have been shown to use exosomes as a novel mechanism 
to transfer the malignant phenotype to normal healthy cells and establish a niche 
for tumor growth. Cancer cell-derived exosomes are reported to contain miRNAs, 
proteins, or long non-coding RNAs that mediate cancer development, growth, and 
progression [42, 43]. Exosomes derived from breast cancer cells contain a variety 
of proteins and RNAs that are transmitted among these cells as well as normal cells, 
thus altering the phenotype of healthy mammary epithelial cells. Wang J et al. 
showed that cancer exosomes were able to transform normal mammary epithelial 
cells into cancerous cells via transfer of microRNAs packaged within exosomes [44]. 
Similarly, Melo et al. showed enhanced expression of exosomal miR-10b in meta-
static breast cells compared to non-metastatic or non-malignant breast cells [45]. 
Thus, it can be used as a therapeutic target for breast cancer therapy.
These characteristics make exosomes ideal biomarkers, and exosomal profiling in 
the absence of tissue holds great promise for early diagnosis. Owing to their crucial 
functional role in breast cancer, exosomes have been investigated for their potential 
development as breast cancer biomarkers and therapeutic targets. Singh R et al. have 
shown that psoralen reduces the formation and secretion of exosomes, thus revers-
ing multidrug resistance in breast cancer cells [46]. The presence of diverse content 
within and on the surface of exosomes has led to their application as biomarkers, 
diagnostics, and drug delivery. A large number of exosomes circulate within bodily 
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fluids of not only healthy individuals but also cancer patients, according to some 
studies. Since exosomes play various significant roles in breast cancer, exosomes can 
be developed as potential therapeutic agents in biomarkers, diagnostics, and drug 
delivery. Kumar et al. investigated the release of exosomes from breast cancer stem 
cells to characterize their constituent exosomal markers. They detected tetraspanin 
proteins, Alix, and tumor susceptibility gene-101 (TSG101) in breast cancer stem 
cell-derived exosomes. This study indicates that secreted exosomes can be utilized 
as biomarkers for breast cancer to understand their development, progression, and 
metastasis [47]. Kumar et al. showed that miRNAs 155 and 205 are expressed in 
serum exosomes derived from breast cancer cells and modulate the epithelial-to-
mesenchymal transition (EMT), growth, and metastasis of cancer, suggesting their 
employability as breast cancer biomarkers [48]. Zhang et al. studied the role of long 
non-coding RNA MALAT 1 which is highly expressed in exosomes derived from 
breast cancer cells in tumor progression, representing a potential treatment strategy 
for breast cancer [49]. Dong et al. investigated the role of exosomal long non-coding 
RNA in the chemoresistance of HER2+ breast cancer cells. They found that exosomal 
lncRNA-SNHG14 was not only upregulated in trastuzumab-resistant cells but also 
transmitted the lncRNA into drug-sensitive cells, thus disseminating trastuzumab 
resistance. Furthermore, when compared to patients who responded to trastuzumab, 
the expression level of serum exosomal lncRNA-SNHG14 was higher in patients who 
were resistant. This suggests that lncRNA-SNHG14 is a promising therapeutic target 
for HER2+ breast cancer patients [50].
5. Engineering exosomes as therapeutics for breast cancer
Exosomes are emerging as promising therapeutic agents because of their role 
in tumor-related processes and their ability to deliver their cargo, such as proteins, 
lipids, and nucleic acids, into the tumor sites. However, their full clinical applicabil-
ity has not yet been realized. This is because of many factors, including low yield 
and relatively low percentage loading to the therapeutic moiety. As such, new 
approaches for mass production and enhancement of the percent loading need to be 
explored. In general, these approaches are divided into two categories: passive and 
active loading, which are discussed in detail in the following sections.
Direct modification, also known as non-cell-based loading or exogenous load-
ing, refers to the direct loading of therapeutic moieties such as siRNA, miRNA, 
drugs, and proteins after the isolation and purification of exosomes from the 
cells. This may encompass a series of procedures such as incubation, freeze-thaw 
cycles, sonication, and electroporation, and thus can further be categorized into 
passive and active loading. Passive loading includes loading of therapeutic moiety 
into exosomes by diffusion; on the other hand, active loading includes disrupting 
the exosomal membrane by electroporation, sonication, or freeze thawing, thus 
allowing the therapeutic moiety to enter into these vesicles. In passive drug load-
ing, exosomes are incubated with drugs and allowed to diffuse into vesicles along 
a concentration gradient. Because exosomes consist of a lipid bilayer, the drug 
loading efficiency depends largely on the hydrophobicity of the drugs. Dong et al. 
loaded curcumin into milk exosomes by incubating at 4°C overnight and reported 
70.46% drug loading using an incubation method [51]. Similarly, Sun et al. 
incorporated curcumin into exosomes derived from a mouse lymphoma cell line 
by incubating in PBS at room temperature (22°C) for 5 min and showed a binding 
capacity of 2.9 g curcumin to 1 g of exosomes [52]. Sun et al. packaged Cho-
miR159 (cholesterol-modified miRNA 159) along with doxorubicin into exosomes 
derived from the human monocytic cell line THP-1 by incubating in PBS at 37°C 
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to deliver to triple-negative breast cancer cells [53]. Linezolid was incorporated 
into exosomes derived from the mouse macrophage cell line RAW 264.7, by mixing 
both and incubating at 37°C for 1 h, resulting in ~5% drug loading. The exosomal 
formulation of linezolid was more effective against MRSA infections than the 
free drug [54]. Although several studies have reported the use of incubation with 
exosomes for drug or any therapeutic agent loading, it often suffers from issues of 
low percent drug loading, urging a requirement for improved methods for higher 
drug loading percent. Another method (less common) of passive loading includes 
incubating the exosome donor cells with the drugs/therapeutic agents. First, 
the donor cells are exposed to drugs or therapeutic agents, followed by isolation 
of released exosomes (supposedly) containing the loaded drugs or therapeutic 
agents. This method was used in a study by Pascucci et al., wherein they exposed 
bone marrow-derived mesenchymal stromal cells (MSCs) with a very high con-
centration of paclitaxel followed by incubation at 37°C for 24 h. After incubation, 
the cells were washed twice with PBS, trypsinized, and seeded in a fresh flask 
for 48 h. After 48 h, cell-conditioned medium was collected to isolate exosomes 
containing paclitaxel. They found that MSC-PTX-derived exosomes had a greater 
inhibitory effect on tumor cell proliferation (Figure 2) [55].
For active cargo loading, the exosomal membrane is temporarily disrupted using 
different methods and then restored once the drug/therapeutic agent was loaded. 
These methods may include sonication, extrusion, freeze-thawing, electroporation, 
use of membrane permeabilizers, conjugation using click chemistry, and antibodies 
against exosomal surface proteins. Electroporation uses an electric field to gener-
ate small pores in the exosomal membrane to disturb the phospholipid bilayer of 
exosomes. Drug/therapeutic agents can enter these vesicles via the generated pores. 
Once they entered, the pores were closed to recover the exosomal membrane integ-
rity. This method has mostly been used to encapsulate siRNA or miRNA into exo-
somes and has been reported to enhance the percent loading compared to the simple 
diffusion method. Jia et al. loaded exosomes derived from RAW 264.7 cells with cur-
cumin and superparamagnetic iron oxide nanoparticles (SPIONs) synchronously 
using optimal electroporation conditions of 400 V, 150 μF, and 1 ms discharge 
time. They observed that electroporation had no effect on the membrane integrity 
of exosomes and efficiently encapsulated curcumin and SPIONs [56]. Similarly, 
Jia et al. incorporated doxorubicin into exosomes isolated from MDA-MB-231 and 
HCT-116 cell lines using an electroporation method, which resulted in ~1.5% drug 
loading [57]. According to published studies, although electroporation enhanced 
the percentage of drug loading in exosomes compared to the incubation method, it 
was still low. Therefore, scientists have employed sonication methods to load cargo 
more efficiently. The mechanical shear force of a sonicator/homogenizer probe is 
applied to disrupt the membrane integrity of exosomes, thus allowing the mixed 
drug/therapeutic agent to enter into the exosomes. In 2017, Kim et al. compared the 
incubation, electroporation, and sonication method of cargo loading in RAW264.7 
cell derived exosomes to develop an exosomal formulation of paclitaxel (PTX). For 
the incubation method, the authors mixed and incubated PTX with exosomes at 
37°C for 1 h. Using electroporation, exosomes and PTX were added to a pre-chilled 
electroporation cuvette and applied at 1000 kV for 5 ms followed by incubation 
at 37°C for half an hour to fully recover the exosome membrane. For sonication, 
the PTX-exosome mixture was sonicated at 20% amplitude, given 6 cycles of 30 s 
on/off for 3 min and a 2 min cooling period between each cycle. After sonication, 
the solution was incubated at 37°C for 1 h to fully recover the membrane of the 
exosomes. They showed the highest percent drug loading of ~28% using sonication 
followed by ~5% using electroporation and the lowest at ~1.4% with the incubation 
method [58].
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Figure 2. 
Illustration representing different methods of cargo loading in exosomes. (A) Passive cargo loading is achieved 
by incubating the therapeutic moiety directly with isolated exosomes or by exposing to the exosome secreting 
donor cells followed by isolation of loaded exosomes. (B) Active cargo loading methods include use of physical 
treatments to disrupt the membrane integrity thus allowing entry of cargo in the interiors of exosomes. These 
treatments include sonication, electroporation, freeze thawing cycles and extrusion method.
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In the extrusion method, exosomes mixed with the drug are passed through 
a syringe-based lipid extruder with a membrane ranging from to 10 to 400 nm 
pore size. In this process, the membrane of exosomes is disrupted by the extensive 
mechanical force of the extruder. In a study by Kim et al. when breast cancer cell-
derived exosomes loaded with porphyrin were extruded, it altered the surface charge 
of blank exosomes, leading to cytotoxic effects [59]. On the other hand, in another 
study by Fuhrmann et al., loading cargo in exosomes using the extrusion method did 
not render them cytotoxic [60]. In the freeze-thaw method, the drug was first incu-
bated with exosomes at ambient temperature and then frozen at −80°C. The mixture 
was then repeatedly thawed at room temperature to ensure drug loading into these 
vesicles. The main disadvantage is that this method often leads to particle aggrega-
tion, resulting in a wide size distribution. This method has also been reported to result 
in a lower percent drug loading than other methods, such as sonication.
6.  Exosomes for drug delivery in breast cancer: progress and future 
promise
Although exosomes have been shown to mediate cancer development, they are 
an emerging platform for drug delivery to cancerous sites because of their excellent 
biocompatibility, low immunogenicity (since they are derived from the patient’s own 
cells), good tolerance, and remarkable biodistribution. Owing to their small size, 
they can readily pass through different bodily barriers such as the blood-brain barrier 
[61]. Compared to synthetic nanoparticles, exosomes are relatively easy to manipulate 
through surface modification in order to enhance their targeting efficiency to cancer 
cells. Recently, the use of exosomes for drug delivery in breast cancer cells has been 
proven to be efficient. Alvarez-Erviti et al. delivered the chemotherapeutic drug 
doxorubicin to breast cancer tissues in a mouse model [62]. First, they engineered 
these cells by expressing Lamp2b, a lysosome-associated membrane glycoprotein 2b, 
on their surface and fused with a targeting peptide for integrins. They then isolated 
exosomes from immature dendritic cells (with low immunogenicity because of the 
absence of immunostimulatory markers on their surface) and used an electroporation 
technique to load doxorubicin within. They have shown that the exosomal formula-
tion of doxorubicin has greater efficiency in targeting mouse tumors and hence, 
exhibits a novel propitious approach in breast cancer treatment in the clinical context. 
Li et al. loaded milk exosomes with doxorubicin to target CD44 overexpressed human 
breast cancer cell lines and found an exosomal formulation capable of delivering the 
drug into cancerous sites in a target-specific manner [63]. Vakshiteh et al. used dental 
pulp-derived mesenchymal stem cells to isolate exosomes and loaded them with 
miRNA, which was then targeted to breast cancer cells. They found that exosomes 
significantly decreased the proliferation of cancer cells and reduced the migratory 
and invasive properties of breast cancer cells in vitro [64, 65]. These studies indicate 
that exosomes are promising candidates for drug delivery in breast cancer therapy.
Currently, there are some hurdles in realizing the clinical potential of exosomes 
as drug delivery nanovehicles. These include low yield, long-term stability, and 
lack of understanding of their therapeutic effects. Hence, more research is required 
to develop techniques that can be used universally to enhance the yield in a time-
efficient manner and increase the stability of exosomes.
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